Xia Yujie, Zhang Bin, Chen Nanrun, Hu Xiaowei, Jin Xinzhe, Lu Chenbin, Liang Feng
Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Qingdao Hospital, University of Health and Rehabilitation Sciences（Qingdao Municipal Hospital）, China.
Heliyon. 2024 Jul 19;10(14):e34810. doi: 10.1016/j.heliyon.2024.e34810. eCollection 2024 Jul 30.
Hepatocellular carcinoma (HCC) is one of the most prevalent and common malignant tumors worldwide, accounting for 85-90 % of primary liver cancer cases. Accumulating evidence shows that long non-coding RNAs (LncRNAs) play regulatory roles in HCC occurrence and progression. However, little is known about the biological role of the LncRNA "E2F1-regulated inhibitor of cell death" (ERICD) in HCC. Our study revealed that ERICD is highly expressed in HCC and correlates with TNM staging; high ERICD levels were associated with poor patient prognoses. We revealed the targeting relationship between ERICD and miR-142-5p for the first time by bioinformatics prediction and further verified the targeting relationship between ERICD and miR-142-5p using a luciferase reporting experiment. In summary, our results showed that ERICD promotes the occurrence and metastasis of HCC by downregulating miR-142-5p expression. Our study provides a target for new potential therapeutic strategies for HCC.
肝细胞癌（HCC）是全球最常见的恶性肿瘤之一，占原发性肝癌病例的85%-90%。越来越多的证据表明，长链非编码RNA（LncRNAs）在HCC的发生和发展中发挥调节作用。然而，关于LncRNA“E2F1调控的细胞死亡抑制剂”（ERICD）在HCC中的生物学作用知之甚少。我们的研究表明，ERICD在HCC中高表达，且与TNM分期相关；ERICD水平高与患者预后不良有关。我们通过生物信息学预测首次揭示了ERICD与miR-142-5p之间的靶向关系，并使用荧光素酶报告实验进一步验证了ERICD与miR-142-5p之间的靶向关系。总之，我们的结果表明，ERICD通过下调miR-142-5p的表达促进HCC的发生和转移。我们的研究为HCC新的潜在治疗策略提供了一个靶点。
